이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Lee's Pharmaceutical Holdings 과거 수익 실적

과거 기준 확인 0/6

Lee's Pharmaceutical Holdings의 수입은 연평균 -3.4%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 5.9%의 비율로 증가했습니다. 매출은 연평균 0.5%의 비율로 감소해 왔습니다. Lee's Pharmaceutical Holdings의 자기자본이익률은 1%이고 순이익률은 1.6%입니다.

주요 정보

-3.4%

수익 성장률

-3.3%

EPS 성장률

Pharmaceuticals 산업 성장	5.6%
매출 성장률	-0.5%
자기자본 수익률	1.0%
순이익	1.6%
최근 수익 업데이트	31 Dec 2023

최근 과거 실적 업데이트

Recent updates

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Have Insiders Sold Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Recently?

Dec 22

Don't Ignore The Fact That This Insider Just Sold Some Shares In Lee's Pharmaceutical Holdings Limited (HKG:950)

Dec 08

Is Lee's Pharmaceutical Holdings Limited's (HKG:950) Recent Price Movement Underpinned By Its Weak Fundamentals?

Dec 01

Is Lee's Pharmaceutical Holdings Limited (HKG:950) A Strong Dividend Stock?

Nov 18

수익 및 비용 분석

Lee's Pharmaceutical Holdings 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SEHK:950 수익, 비용 및 수입 (HKD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Dec 23	1,053	17	494	97
30 Sep 23	980	5	472	75
30 Jun 23	1,096	39	495	101
31 Mar 23	1,165	39	520	132
31 Dec 22	1,233	51	545	169
30 Sep 22	1,350	-119	717	230
30 Jun 22	1,331	-140	753	248
31 Mar 22	1,308	1,966	766	258
31 Dec 21	1,266	1,987	754	244
30 Sep 21	1,275	2,176	626	241
30 Jun 21	1,244	2,188	574	241
31 Mar 21	1,227	130	534	226
31 Dec 20	1,217	129	519	203
30 Sep 20	1,199	167	522	177
30 Jun 20	1,168	184	512	146
31 Mar 20	1,209	118	508	141
31 Dec 19	1,219	126	491	150
30 Sep 19	1,185	301	471	174
30 Jun 19	1,177	331	442	168
31 Mar 19	1,139	395	403	156
31 Dec 18	1,138	418	411	153
30 Sep 18	1,126	243	380	123
30 Jun 18	1,101	233	377	112
31 Mar 18	1,064	256	393	96
31 Dec 17	1,009	233	371	85
30 Sep 17	981	245	348	77
30 Jun 17	955	256	347	72
31 Mar 17	930	245	348	74
31 Dec 16	930	252	351	68
30 Sep 16	911	259	337	61
30 Jun 16	894	247	332	50
31 Mar 16	917	242	348	41
31 Dec 15	922	229	369	39
30 Sep 15	976	221	415	32
30 Jun 15	990	209	435	37
31 Mar 15	979	191	426	40
31 Dec 14	955	193	409	38
30 Sep 14	874	175	378	45
30 Jun 14	805	164	351	40
31 Mar 14	755	160	326	38
31 Dec 13	697	150	301	32
30 Sep 13	658	140	283	26

양질의 수익: 950 에는 HK$6.9M 큰 일회성 득실이 있습니다. HK$6.9M 은 지난 12개월 간의 재무 결과에 31st December, 2023 까지 영향을 미쳤습니다.

이익 마진 증가: 950 의 현재 순이익 이익률 (1.6%) 작년보다 낮습니다 (4.2%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 950 의 수입은 지난 5년 동안 매년 3.4% 씩 감소했습니다.

성장 가속화: 950 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.

수익 대 산업: 950 은 지난 1년 동안 마이너스 수익 성장( -67.4% )을 기록하여 Pharmaceuticals 업계 평균( 1.3% ).

Lee's Pharmaceutical Holdings 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Recent updates

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Upcoming dividend of HK$0.01 per share

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Board Member recently bought HK$231k worth of stock

Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate

Board Member recently bought HK$381k worth of stock

First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021)

Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate

Upcoming dividend of HK$0.031 per share

Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022

Price target decreased to HK$4.85

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020)

Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022

Price target decreased to HK$5.30

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Lee's Pharmaceutical Holdings Limited Obtains Approval from the Center for Drug Evaluation

Second quarter 2021 earnings released: EPS HK$3.59 (vs HK$0.097 in 2Q 2020)

Investor sentiment deteriorated over the past week

Non-Executive Director Simon Miles Ball has left the company

Price target decreased to HK$6.42

First quarter 2021 earnings released: EPS HK$0.07 (vs HK$0.068 in 1Q 2020)

Price target decreased to HK$6.92